Chimeric antigen receptor T (CAR-T ... CD3+ T cells were magnetically purified from the peripheral blood mononuclear cells (PBMCs) of health donors and then activated with anti-CD3/CD28 Dynabeads ...

Chimeric antigen receptor (CAR)-T ... vector. The CAR sequence was preceded by the RQR8 tag separated by a short T2A peptide for detection (25). The preparation of the lentivirus was performed ...

To create one of the most advanced immunotherapies in cancer, CAR-T cell therapies, scientists engineer immune T cells to carry a synthetic protein on their surfaces. This protein, called the ...

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

Transient mRNA-based CAR T cell therapy has emerged as a promising approach for the treatment of autoimmune diseases. Traditional CAR T cell therapy uses lentiviral or gammaretroviral vectors to ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six ...

There were no bands observed for the vector control lane as expected. To assess the cytotoxicity of CD5CAR NK-92 cells against normal T-cells ... of high efficiency CAR transduction that may ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Patients with and without preexisting autoimmune or inflammatory disease show similar safety and cancer outcomes after chimeric antigen receptor (CAR) T-cell therapy for cancer. Researchers ...

Within a large group of more than 700 patients treated with CAR T cell therapy ... Jadlowsky et al, Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies, Nature ...